Monte Rosa Therapeutics, Inc. (GLUE) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Jun 5, 2026
Current Price
$17.10
Price Target
$31.75
Target Range
$22.00 — $37.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-37.2x
Forward PEG—
Implied Growth+16.5%
Median Target$34.00
Analyst Spread47.2%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$22
+28.7%
Consensus
$32
+85.7%
Bull Case
$37
+116.4%
GLUE Price Target Analysis
Updated June 12, 2026As of June 12, 2026, Monte Rosa Therapeutics, Inc. (GLUE) has a Wall Street consensus price target of $31.75, based on estimates from 9 covering analysts. With the stock currently trading at $17.10, this represents a potential upside of +85.7%. The company has a market capitalization of $1.11B.
Analyst price targets range from a low of $22.00 to a high of $37.00, representing a 47% spread in expectations. The median target of $34.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GLUE trades at a trailing P/E of -37.2x. Analysts expect EPS to grow +16.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+45.9%
Avg Forward P/E32.4x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ARVNArvinas, Inc. | $457M | $7.09 | $14.75 | +108.0% | Buy | — | 26 |
 KYMRKymera Therapeutics, Inc. | $6.8B | $82.96 | $119.93 | +44.6% | Buy | — | 26 |
 PRAXPraxis Precision Medicines, Inc. | $7.2B | $247.98 | $595.93 | +140.3% | Buy | — | 16 |
 VRTXVertex Pharmaceuticals Incorporated | $113.2B | $445.04 | $553.93 | +24.5% | Buy | 23.1x | 56 |
 BEAMBeam Therapeutics Inc. | $3.0B | $29.41 | $48.00 | +63.2% | Buy | — | 27 |
 IMVTImmunovant, Inc. | $6.8B | $32.88 | $43.67 | +32.8% | Buy | — | 23 |
 PTGXProtagonist Therapeutics, Inc. | $7.1B | $109.79 | $115.40 | +5.1% | Buy | 27.2x | 26 |
 CRLCharles River Laboratories International, Inc. | $9.1B | $188.06 | $213.17 | +13.4% | Buy | 17.0x | 37 |
 MEDPMedpace Holdings, Inc. | $13.6B | $475.07 | $498.86 | +5.0% | Hold | 28.0x | 19 |
 RGENRepligen Corporation | $7.5B | $133.33 | $163.14 | +22.4% | Buy | 66.6x | 24 |
Upside Potential Comparison
PRAXARVNBEAMKYMRIMVTVRTXRGENCRLWhat if you invested $1,000 in GLUE 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in GLUE be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs GLUE Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationGLUE vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowGLUE — Frequently Asked Questions
Quick answers to the most common questions about buying GLUE stock.
What is the GLUE stock price target for 2026?
The consensus Wall Street price target for GLUE is $31.75, representing 85.7% upside from the current price of $17.1. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is GLUE a buy, sell, or hold?
GLUE has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $31.75 implies 85.7% upside from current levels.
Is GLUE stock overvalued or undervalued?
GLUE's current price is $17.1 with a consensus target of $31.75 (85.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can GLUE stock go?
The most bullish Wall Street analyst has a price target of $37 for GLUE, while the most conservative target is $22. The consensus of $31.75 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover GLUE stock?
GLUE is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GLUE stock forecast?
The 12-month GLUE stock forecast based on 9 Wall Street analysts shows a consensus price target of $31.75, with estimates ranging from $22 (bear case) to $37 (bull case). The median consensus rating is "Buy".
Should I buy GLUE stock?
Wall Street analysts are very optimistic on GLUE, with a "Buy" consensus rating and $31.75 price target (85.7% upside). 7 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GLUE price targets vary so much?
GLUE analyst price targets range from $22 to $37, a 47% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $31.75 consensus represents the middle ground.